• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Brain Injury - Pipeline Review, H2 2012 Product Image

Brain Injury - Pipeline Review, H2 2012

  • ID: 2366318
  • December 2012
  • 42 pages
  • Global Markets Direct

Brain Injury – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Brain Injury - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Brain Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Injury. Brain Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Brain Injury.
- A review of the Brain Injury products under development by companies and universities/research institutes based on information derived READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Brain Injury Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Brain Injury 7
Brain Injury Therapeutics under Development by Companies 9
Brain Injury Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Brain Injury Therapeutics – Products under Development by Companies 14
Brain Injury Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Brain Injury Therapeutics Development 16
CardioVascular BioTherapeutics, Inc. 16
Proneuron Biotechnologies, Inc. 17
Theraptosis S.A. 18
MAPREG 19
Brain Injury – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
CVBT-141F - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
TRP-601 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
epoetin alfa - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
somatropin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Poly-YE Neuroprotective Vaccine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
glyburide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
cycloserine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
hydroxyurea - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Metformin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Adiponectin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MAP-4343 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Brain Injury Therapeutics - Dormant Products 36
Brain Injury – Product Development Milestones 38
Featured News & Press Releases 38
Jun 08, 2012: Government Of Canada Awards CAD700,000 Toward Phase II Study Of Edge Therapeutics's Lead Compound To Improve Outcomes After Brain Injury 38
Feb 11, 2011: Edge Therapeutics's NimoGel Shows Promise At Preventing Delayed Complications Of Sudden Brain Injury In Preclinical Study 38
Nov 09, 2009: ReGen's Study Reports Positive Results Of Zolpidem In Brain Damage 39
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Number of Products Under Development for Brain Injury, H2 2012 7
Products under Development for Brain Injury – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
CardioVascular BioTherapeutics, Inc., H2 2012 16
Proneuron Biotechnologies, Inc., H2 2012 17
Theraptosis S.A., H2 2012 18
MAPREG, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Brain Injury Therapeutics – Dormant Products 36
Brain Injury Therapeutics – Dormant Products (Contd..1) 37

List of Figures
Number of Products under Development for Brain Injury, H2 2012 7
Products under Development for Brain Injury – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos